DoubleCHEK key facts
as of Oct 2026- Developer of medical devices designed to improve enteral access by enabling safer placement of nasogastric feeding and decompression tubes.
- DoubleCHEK is valued at approximately $8.3M as of Oct 2026 (last reported valuation).
- It has raised $3.1M; the latest was Later Stage VC ($3.1M) in Nov 2025.
- Notable investors include British Business Bank, Puffin Point, British Design Fund, Freyr Investments, Namier Capital Partners — 6 tracked in total.
- Status: Privately Held (backing).
DoubleCHEK's last reported valuation, Nov 2025. Nothing priced has surfaced since.
- ·Watch DoubleCHEK: the Monday email on marks, rounds and moves
DoubleCHEK funding rounds
No funding rounds for DoubleCHEK are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
DoubleCHEK valuation
DoubleCHEK's last reported valuation was $8.3 million in Nov 2025. No priced round, secondary trade or fund mark has surfaced since.
DoubleCHEK investors
6 investors are on record for DoubleCHEK, including British Business Bank, Puffin Point, British Design Fund and Freyr Investments.
About DoubleCHEK
Developer of medical devices designed to improve enteral access by enabling safer placement of nasogastric feeding and decompression tubes. The company offers a tube-compatible device with dual carbon dioxide and pH indicators, enabling clinicians working with infants to reduce misplacements, avoid lung insertion, and minimize unnecessary radiation exposure.
- Sector
- Healthcare
- HQ
- Liverpool, United Kingdom
- Founded
- 2018
- Employees
- 10
- Website
- enteralaccesstech.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.